Xconomy Boston — It hasn’t been proven yet that synthetic messenger RNA molecules (mRNA) can be effective medicines. Sanofi Pasteur will invest $45m for the rights to experimental vaccines using messenger RNA (mRNA) molecules for up to five infectious diseases developed by US firm Translate Bio. Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, aims to harness the mRNA technology to create "next-generation vaccines", according to senior VP of R&D John Shiver. The investment is part of a larger deal between Sanofi and Translate, which has already raised $200m in funding from investors including Google Ventures and Kleiner Perkins Caufield & Byers.
Sanofi Pasteur will invest $45m for the rights to experimental vaccines using messenger RNA (mRNA) molecules for up to five infectious diseases developed by US firm Translate Bio. Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, aims to harness the mRNA technology to create "next-generation vaccines", according to senior VP of R&D John Shiver. The investment is part of a larger deal between Sanofi and Translate, which has already raised $200m in funding from investors including Google Ventures and Kleiner Perkins Caufield & Byers.